메뉴 건너뛰기




Volumn 45, Issue 2, 2007, Pages 88-93

Antimycobacterial activity from cyanobacterial extracts and phytochemical screening of methanol extract of Hapalosiphon

Author keywords

Antimycobacterial; Cyanobacteria; Hapalosiphon sp.

Indexed keywords

METHANOL DERIVATIVE; PETROLEUM DERIVATIVE;

EID: 33947281006     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880200601105319     Document Type: Article
Times cited : (21)

References (20)
  • 1
    • 51249168726 scopus 로고
    • Microalgae as sources of pharmaceuticals and other biologically active compounds
    • Borowitzka MA (1995): Microalgae as sources of pharmaceuticals and other biologically active compounds. Appl Phycol 7: 3-15.
    • (1995) Appl Phycol , vol.7 , pp. 3-15
    • Borowitzka, M.A.1
  • 2
    • 33947282294 scopus 로고    scopus 로고
    • Marine cyanobacteria prolific source of natural products
    • Burja AM (2001): Marine cyanobacteria prolific source of natural products. Tetrahedron 57: 9437-9477.
    • (2001) Tetrahedron , vol.57 , pp. 9437-9477
    • Burja, A.M.1
  • 3
    • 0030903133 scopus 로고    scopus 로고
    • Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium
    • Collins L, Franzblau SG (1997): Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41: 1004-1009.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1004-1009
    • Collins, L.1    Franzblau, S.G.2
  • 4
    • 0347063673 scopus 로고    scopus 로고
    • Antimycobacterial natural products
    • Copp BR (2003): Antimycobacterial natural products. Nat Prod Res 20: 535-537.
    • (2003) Nat Prod Res , vol.20 , pp. 535-537
    • Copp, B.R.1
  • 5
    • 0031028432 scopus 로고    scopus 로고
    • Natural products in drug discovery and development
    • Cragg GM, Newman DJ, Snader KMJ (1997): Natural products in drug discovery and development. J Nat Prod 60: 52-60.
    • (1997) J Nat Prod , vol.60 , pp. 52-60
    • Cragg, G.M.1    Newman, D.J.2    Snader, K.M.J.3
  • 6
    • 0033581124 scopus 로고    scopus 로고
    • Consensus statement on global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project
    • Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999): Consensus statement on global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: 677-686.
    • (1999) JAMA 282 , pp. 677-686
    • Dye, C.1    Scheele, S.2    Dolin, P.3    Pathania, V.4    Raviglione, M.C.5
  • 7
    • 0037316411 scopus 로고    scopus 로고
    • Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
    • Edelman MJ, Gandera DR, Hausner P, Israel V, Thornion D, De Santo J, Doyle LA (2003): Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39: 197-199.
    • (2003) Lung Cancer , vol.39 , pp. 197-199
    • Edelman, M.J.1    Gandera, D.R.2    Hausner, P.3    Israel, V.4    Thornion, D.5    De Santo, J.6    Doyle, L.A.7
  • 9
    • 33947191074 scopus 로고    scopus 로고
    • Glombitza KW, Koch M (1989): Secondary metabolites of pharmaceutical potential. In: Algal and Cyanobacterial Biotechnology. eds. Crosswell RC, Rees Tav, Shah N. p. 161-238. Harlow, UK: Longmann Scientific and Technical pp. 161-238.
    • Glombitza KW, Koch M (1989): Secondary metabolites of pharmaceutical potential. In: Algal and Cyanobacterial Biotechnology. eds. Crosswell RC, Rees Tav, Shah N. p. 161-238. Harlow, UK: Longmann Scientific and Technical pp. 161-238.
  • 10
    • 18844444472 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors
    • Jonge MJ, Van der Gaast A, Planting AS, Van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J (2005): Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806-3813.
    • (2005) Clin Cancer Res , vol.11 , pp. 3806-3813
    • Jonge, M.J.1    Van der Gaast, A.2    Planting, A.S.3    Van Doorn, L.4    Lems, A.5    Boot, I.6    Wanders, J.7    Satomi, M.8    Verweij, J.9
  • 11
    • 0032998558 scopus 로고    scopus 로고
    • Cyanobacteria - a potential source of new biologically active substances
    • Kreitlow S, Sabine M (1999): Cyanobacteria - a potential source of new biologically active substances. J Biotech 70: 61-63.
    • (1999) J Biotech , vol.70 , pp. 61-63
    • Kreitlow, S.1    Sabine, M.2
  • 12
    • 0028994790 scopus 로고
    • The potential for using cyanobacteria (blue green algae and algae) in the biological control of plant pathogenic bacteria and fungi
    • Kulik MM (1995): The potential for using cyanobacteria (blue green algae and algae) in the biological control of plant pathogenic bacteria and fungi. Eur J Plant Pathol 10: 585-599.
    • (1995) Eur J Plant Pathol , vol.10 , pp. 585-599
    • Kulik, M.M.1
  • 13
    • 0042889069 scopus 로고    scopus 로고
    • Biological screening of terrestrial and fresh water cyanobacterial for antimicrobial activity, brine shrimp lethality and cytotoxicity
    • Mian P, Heilman J, Burgi HR, Sticher O (2003): Biological screening of terrestrial and fresh water cyanobacterial for antimicrobial activity, brine shrimp lethality and cytotoxicity. Pharm Biol 41: 243-247.
    • (2003) Pharm Biol , vol.41 , pp. 243-247
    • Mian, P.1    Heilman, J.2    Burgi, H.R.3    Sticher, O.4
  • 14
    • 33947256966 scopus 로고    scopus 로고
    • National Committee for Clinical Laboratory Standards (2000): Susceptibility Testing of Mycobacteria, Nocardia, and other Aerobic Actinomycetes: Tentative Standard M24-T2 NCCLS. 20: No. 26. 2nd ed. 20; no. 26. NCBI Taxonomy Browser, August 30, 2004.
    • National Committee for Clinical Laboratory Standards (2000): Susceptibility Testing of Mycobacteria, Nocardia, and other Aerobic Actinomycetes: Tentative Standard M24-T2 NCCLS. 20: No. 26. 2nd ed. vol. 20; no. 26. NCBI Taxonomy Browser, August 30, 2004.
  • 15
    • 0000424792 scopus 로고
    • Bioactive natural products from blue green algae
    • Patterson GM, Larson LK, Moore RE (1994): Bioactive natural products from blue green algae. J Appl Phycol 6: 151-157.
    • (1994) J Appl Phycol , vol.6 , pp. 151-157
    • Patterson, G.M.1    Larson, L.K.2    Moore, R.E.3
  • 17
    • 0000961750 scopus 로고
    • Archean microfosssils: New evidence of ancient microbes
    • Schopf JW, ed, Princeton, Princeton University Press, p
    • Schopf JW, Walter WR (1983): Archean microfosssils: New evidence of ancient microbes. In: Schopf JW, ed., Earth's Earliest Biosphere: Its Origin and Evolution. Princeton, Princeton University Press, p. 214.
    • (1983) Earth's Earliest Biosphere: Its Origin and Evolution , pp. 214
    • Schopf, J.W.1    Walter, W.R.2
  • 20
    • 0033961732 scopus 로고    scopus 로고
    • The role of natural products in a modern drug discovery program
    • Strohl WR (2000): The role of natural products in a modern drug discovery program. Drug Discovery Today 5: 39-41.
    • (2000) Drug Discovery Today , vol.5 , pp. 39-41
    • Strohl, W.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.